-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum AB (publ) Announces Positive Preclinical Data on Ilixadencel in Combination with CTLA-4 Immune Checkpoint Inhibitor
21 Oct 2019Immunicum AB (publ) Announces Nomination Committee for AGM 2020
14 Oct 2019Immunicum AB (publ) Announces Advancement to Next Dosage Group Level in Phase Ib/II ILIAD Combination Trial
01 Oct 2019
News
-
RedEye Interview with CEO Carlos de Sousa
16 Oct 2019 -
Edison Report from 11 October 2019
16 Oct 2019 -
MERECA Q&A – Swedish
25 Sep 2019 -
Webcast Link & Presentation Slides
25 Sep 2019 -
MERECA Q&A – English
25 Sep 2019
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
